about
Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effectsCOMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor featuresCollective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion programPeripheral nervous system involvement in Parkinson's disease: evidence and controversiesAutosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's diseaseA reassessment of risks and benefits of dopamine agonists in Parkinson's diseaseValvular heart disease and the use of dopamine agonists for Parkinson's diseaseStriatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's diseaseContinuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyEFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease.The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature.Parkinson's disease, chronic hydrocarbon exposure and striatal neuronal damage: a 1-H MRS study.Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy.Novel parkin mutations detected in patients with early-onset Parkinson's disease.PD_Manager: an mHealth platform for Parkinson's disease patient management.Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy.Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale.An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.Dopamine Transporter SPECT Imaging in Corticobasal Syndrome.Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathiesCognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need.Role of pramipexole in the management of Parkinson's disease.Anatomical correlates of cognitive functions in early Parkinson's disease patients.Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.Functional neuroimaging (PET and SPECT) in the selection and assessment of patients with Parkinson's disease undergoing deep brain stimulation.The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor.The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project.Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleusBrain SPECT imaging in multiple system atrophy.The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients"Gunslinger's gait": a new cause of unilaterally reduced arm swing.Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study.MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up studyRole of DAT-SPECT in the diagnostic work up of parkinsonism.Continuous dopaminergic stimulation--from theory to clinical practice.Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies.New strategies in motor parkinsonism.
P50
Q24631118-DFA0C90C-00FA-4378-AF45-5A22B528D292Q24644555-A3D5E044-A0F6-46EC-B52E-DE372B48AD1CQ26800233-F14BC18A-4245-442F-BB1E-F193F44BFF1DQ27014823-9C552C76-4E61-4C1F-8F55-E4315A20D791Q28205082-D5E2242E-7D34-4439-BFE0-AD10A0B840ADQ28241323-E30B496B-BB02-4483-B1C4-336000324ECDQ28256463-CD1537B5-28CB-4060-937E-50019F82B036Q28281832-70077534-B80B-4B75-9EC5-FACF27D79D8DQ28302222-19EFD471-2FA1-4C59-B75E-86025F9D3169Q30366253-3B53ABED-697A-4A59-9BF9-9D665C2B42A9Q30583771-62D6FA8A-773D-41F7-AE6C-1909800E8974Q31008210-DD9CC343-9AE3-4F3E-8C3C-0D07E1267AB0Q31013183-F957EEB8-EAD8-4AC3-98AD-A1090CEC217FQ31025178-0C4A6255-DCD3-4475-BFF2-1D07293D4EB5Q33209648-566D5013-BD45-46D1-AC66-176D6E74800AQ33455579-BC5419E3-0F7B-488F-8BD7-4B2FB07C1671Q33732095-E9B2225A-6064-49EF-B054-8D8F2AA3BAA2Q33766006-339B47A3-5645-43B0-B056-A785E3829DACQ33890861-E2554A6E-B2AB-46A1-9F85-1F453A6CF308Q33894779-51D83BB3-01E8-4CDA-848C-E977B5A3F26EQ34078528-52EB927F-5986-484D-A1AE-04651169D885Q34245237-F2B3EE72-D2D4-479B-9D5C-EE3317BCB3FEQ34611889-1BCC7CE6-4EB5-4A97-A91C-A45CF4C89AB3Q34623437-E25E8583-A4B6-4A21-B314-F09C0AB3EA4BQ34745456-EFDC1D01-EE57-47F7-A1B2-BF9B3F934F57Q35006707-362B0B0C-123C-42B0-8F7F-B97836CB74FCQ35192882-73E49DF0-84D2-405A-936B-F37F6D88F40AQ35447263-B27A119D-8D13-442E-A7C1-06133C7833C7Q35608939-5461B551-E310-4B24-B1D7-4342701A2749Q36142302-8E93D97B-71F6-46BA-9495-DF298A9DC36EQ36311949-7D0E6537-6A72-4339-B2DB-ED3DD3C01C87Q36332532-42D49C37-2618-4258-B8C3-F1BABBFEE001Q36366224-22EA1D59-1F41-49A9-AB18-A22F14A5CFBDQ36369299-8D3FBBDF-E8B9-41B1-A6C1-1DB242B22263Q36738260-AFDE2D68-86B4-4461-84C8-069E30A14AAEQ36763084-8B0E20B7-6F76-48E3-94B2-DB8C64512E2CQ36814559-C54DDBD9-EBD9-44FE-81C7-D1EB099CF0D0Q36911936-357F7D5E-C901-400D-A19D-E42BEDA4A92BQ36993516-0745F9BB-5613-4BE2-881D-F1AB86391CD0Q37082137-B37BA6C1-A470-4CE1-8179-397600875EC2
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Angelo Antonini
@ast
Angelo Antonini
@en
Angelo Antonini
@es
Angelo Antonini
@nl
Angelo Antonini
@sl
type
label
Angelo Antonini
@ast
Angelo Antonini
@en
Angelo Antonini
@es
Angelo Antonini
@nl
Angelo Antonini
@sl
altLabel
A Antonini
@en
Antonini A
@en
prefLabel
Angelo Antonini
@ast
Angelo Antonini
@en
Angelo Antonini
@es
Angelo Antonini
@nl
Angelo Antonini
@sl
P4012
P214
P244
P1053
K-2065-2016
P106
P1153
7102486937
P1960
d-7hXbgAAAAJ
P2038
Angelo_Antonini
P21
P214
P244
n2013183244
P2798
P31
P3829
P3835
angelo-antonini2
P4012
P496
0000-0003-1040-2807
P734
P735
P7859
lccn-n2013183244